Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes

Progression-free survival (PFS) of patients with lower-risk myelodysplastic syndromes (MDS) treated with red blood cell transfusions is usually reduced, but it is unclear whether transfusion dose density is an independent prognostic factor. The European MDS Registry collects prospective data at 6-mo...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Haematologica
Päätekijät: de Swart, Louise, Crouch, Simon, Hoeks, Marlijn, Smith, Alex, Langemeijer, Saskia, Fenaux, Pierre, Symeonidis, Argiris, Cermâk, Jaroslav, Hellström-Lindberg, Eva, Stauder, Reinhard, Sanz, Guillermo, Mittelman, Moshe, Holm, Mette Skov, Malcovati, Luca, Mądry, Krzysztof, Germing, Ulrich, Tatic, Aurelia, Savic, Aleksandar, Almeida, Antonio Medina, Gredelj-Simec, Njetocka, Guerci-Bresler, Agnes, Beyne-Rauzy, Odile, Culligan, Dominic, Kotsianidis, Ioannis, Itzykson, Raphael, van Marrewijk, Corine, Blijlevens, Nicole, Bowen, David, de Witte, Theo
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Ferrata Storti Foundation 2020
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7049377/
https://ncbi.nlm.nih.gov/pubmed/31171638
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.212217
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia